For the roughly 25 million Americans who live with persistent ringing in their ears, the cause is often maddeningly unclear. Now a study published in May 2026 in the Proceedings of the National Academy of Sciences has identified a specific brain circuit that may help explain one underrecognized trigger: the very medications millions of people take for depression and anxiety.
Researchers at Oregon Health & Science University found that a serotonin-releasing pathway running from the brain’s main serotonin-producing region to a key auditory processing center can amplify tinnitus-like behavior in mice. The discovery offers the first clear mechanistic link between elevated serotonin and phantom sound perception, raising pointed questions about a trade-off that clinicians have long suspected but never been able to explain at the circuit level.
The circuit behind the ringing
The study, led by neuroscientist Laurence Trussell and colleagues at OHSU, mapped a discrete pathway connecting the dorsal raphe nucleus, the brain’s primary serotonin factory, to the dorsal cochlear nucleus, a relay station in the auditory brainstem that processes sound before it reaches higher brain regions.
When the team boosted serotonin signaling along this pathway in mice, the animals showed stronger behavioral markers of tinnitus. When they silenced the same connection, those markers dropped. Crucially, the researchers used circuit-level manipulations that allowed them to test causality, not just correlation, a significant step beyond earlier observational work.
The result builds on roughly a decade of converging evidence. Previous research showed that serotonergic neurons in the dorsal raphe become active during chemically induced tinnitus in rodents, establishing that the serotonin system responds when tinnitus is present. Separate electrophysiology work demonstrated that serotonin has predominantly excitatory effects on dorsal cochlear nucleus neurons, meaning more serotonin tends to make those cells fire more aggressively, even in the absence of actual sound.
The dorsal cochlear nucleus itself has been firmly established as a critical node in tinnitus generation. Earlier experiments showed that mice exhibiting tinnitus-like behavior had hyperactive neurons in this region due to reduced inhibitory signaling. And in a separate animal model, bilateral lesions of the dorsal cochlear nucleus prevented tinnitus from developing after acoustic trauma entirely. The picture these studies paint is consistent: the dorsal cochlear nucleus is where tinnitus signals are generated or amplified, and serotonin arriving from the dorsal raphe can push that activity higher.
Why this does not translate to humans yet
Every finding so far comes from mice, not people. The behavioral tests used to detect tinnitus in rodents rely on indirect measures, such as changes in startle reflexes or gap detection, rather than the subjective experience of phantom sound that defines tinnitus in a doctor’s office. Whether the same dorsal raphe-to-dorsal cochlear nucleus circuit operates identically in the human brain has not been tested.
There are also no controlled clinical trials showing that SSRIs or SNRIs systematically worsen tinnitus in patients. Clinicians have reported anecdotal cases for years, and some patients describe new or louder ringing after starting serotonin-boosting medications, but controlled longitudinal studies tracking tinnitus severity during chronic antidepressant use remain absent from the published literature. It is worth noting that the mouse experiments used acute circuit manipulations rather than weeks-long drug exposure, so they do not replicate the pharmacological reality of someone taking a daily SSRI.
The study also does not identify which serotonin receptor subtypes drive the effect. Serotonin acts through a large family of receptor types, and the dorsal cochlear nucleus expresses several of them. In theory, a targeted receptor blocker acting on one of these subtypes could suppress tinnitus-related hyperactivity without disrupting the mood benefits of elevated serotonin elsewhere in the brain. The 5-HT2C receptor is one candidate that researchers have discussed, though it is only one of several possibilities and no selective pharmacological intervention targeting it or any other subtype was reported in the PNAS paper.
What this means for people taking antidepressants
To be direct: no one should stop taking prescribed antidepressants based on a mouse study. The research identifies a biological mechanism, not a treatment recommendation. SSRIs and SNRIs remain among the most effective and widely prescribed treatments for depression and anxiety.
For patients who already experience tinnitus and take serotonin-boosting medications, the findings offer a plausible biological explanation for why their symptoms might fluctuate. But the appropriate response is a conversation with a prescribing physician, not a medication change made in isolation.
The practical gap between this laboratory work and a usable therapy remains wide. Researchers would need to pinpoint the specific receptor mediating the effect, develop or repurpose a drug that blocks it selectively in the auditory brainstem, and then run human trials to confirm safety and efficacy. Each of those steps typically takes years.
From vague association to defined circuit target
What makes the PNAS paper a meaningful advance is the shift it represents: from “serotonin might be involved in tinnitus” to “this specific pathway drives the behavior in an animal model.” That distinction matters enormously for drug development. Instead of chasing a vague association, researchers now have a defined circuit and a defined chemical signal to target.
For the millions of people who endure tinnitus with no effective treatment, that kind of precision is exactly what has been missing. The ringing may not stop tomorrow, but for the first time, scientists can point to the wiring diagram that may be responsible.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
